Table 1 Study subject characteristics
| Â | Â | # of Subjects | |
|---|---|---|---|
| Â | Â | Low PV Dose | High PV Dose |
Subjects | Â | 27 | 28 |
Gender | Male | 18 | 12 |
| Â | Female | 9 | 16 |
Mean Age at RT (range) |  | 52 ± 6 (25-82) | 51 ± 5 (26-77) |
Glioma Grade | Grade 3 | 8 | 9 |
| Â | Grade 4 | 19 | 19 |
Racial-Ethnicity | Caucasian | 25 | 26 |
| Â | Asian | 2 | 2 |
Surgical Co-Intervention | Biopsy-only | 2 | 5 |
| Â | Total Resection | 16 | 6 |
| Â | Subtotal Resection | 9 | 17 |
Drug Co-intervention | Temodar | 27 | 27 |
| Â | Avastin | 5 | 9 |
| Â | Other | 8 | 3 |
Median Karnofsky Perf. Scale (range) | Â | 90% (70-100%) | 90% (50-90%) |
Mean RPA Classification | # of RPA Class III | 8 | 8 |
| Â | # of RPA Class IV | 11 | 8 |
| Â | # of RPA Class V | 8 | 12 |
MGMT Status | Methylated | 2 | 6 |
| Â | Unmethylated | 5 | 6 |
| Â | Unknown | 20 | 16 |
Tumor Localization | Frontal | 6 | 11 |
| Â | Temporal | 12 | 10 |
| Â | Parietal | 4 | 3 |
| Â | Occipital | 2 | 1 |
| Â | Other | 3 | 3 |
Mean Bilateral PV Dose |  | 27 Gy ± 5 | 50 Gy ± 2 |
Median Ipsilateral PV Dose |  | 46 Gy ± 15.5 | |
Median Contralateral PV Dose |  | 41 Gy ± 16.1 | |
Median Ipsilateral HF Dose |  | 49.9 Gy ± 16.3 | |
Mean Total Prescription Dose (range) |  | 52 Gy ± 4 (30-63) | 57 Gy ± 2 (45-60) |